Hikma Pharmaceuticals (LON:HIK) Price Target Raised to GBX 1,870

Key Points

• Jefferies raised the price target on Hikma to GBX 1,870 (from GBX 1,850) and kept a "buy" rating, implying roughly a 29.77% upside from the prior close.
• Analyst consensus is positive: five analysts rate the stock "Buy" with a consensus target of GBX 2,128, while individual targets range (e.g., Berenberg GBX 1,800; Deutsche Bank GBX 2,400).
• Key stock metrics: shares opened at GBX 1,441, market cap £3.12 billion, PE 7.96, and a 12‑month range of GBX 1,187–2,164.

Hikma Pharmaceuticals (LON:HIK - Get Free Report) had its price objective lifted by investment analysts at Jefferies Financial Group from GBX 1,850 to GBX 1,870 in a research note issued on Tuesday,Digital Look reports. The brokerage presently has a "buy" rating on the stock. Jefferies Financial Group's target price points to a potential upside of 29.77% from the stock's previous close.

Several other brokerages also recently commented on HIK. Berenberg Bank reaffirmed a "buy" rating and set a GBX 1,800 price objective on shares of Hikma Pharmaceuticals in a research note on Tuesday, April 28th. Deutsche Bank Aktiengesellschaft dropped their price objective on Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set a "buy" rating on the stock in a research note on Friday, January 9th. Five research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of GBX 2,128.

Hikma Pharmaceuticals Stock Performance

Shares of Hikma Pharmaceuticals stock opened at GBX 1,441 on Tuesday. The company has a market capitalization of £3.12 billion, a PE ratio of 7.96, a PEG ratio of 2.38 and a beta of 0.61. Hikma Pharmaceuticals has a 12 month low of GBX 1,187 and a 12 month high of GBX 2,164. The company has a current ratio of 1.82, a quick ratio of 1.27 and a debt-to-equity ratio of 63.59. The stock's fifty day simple moving average is GBX 1,322.61 and its 200 day simple moving average is GBX 1,500.84.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.